There are 3397 resources available
1325P - Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations
Presenter: James Chih-Hsin Yang
Session: Poster session 19
1326P - Osimertinib in patients with EGFR-mutated NSCLC and leptomeningeal or brain metastases: Results of the IFCT-1804 ORBITAL trial
Presenter: David Planchard
Session: Poster session 19
1327P - First-line osimertinib in patients with EGFR mutated lung cancer with uncommon mutations (OCELOT study – interim analysis)
Presenter: Daniel Breadner
Session: Poster session 19
1328P - Analysis of data from the AENEAS study assessing the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), aumolertinib, and virtual comparison with osimertinib
Presenter: Meredith LaRose
Session: Poster session 19
1329P - FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC
Presenter: Lucia Nogova
Session: Poster session 19
1330P - Updated results of the efficacy and safety of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer (NSCLC) who failed prior EGFR-TKI(s)
Presenter: Caicun Zhou
Session: Poster session 19
1333P - A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations
Presenter: Min Hee Hong
Session: Poster session 19
1334P - Activity of first line immunotherapy or chemo-immunotherapy in advanced NSCLC with SMARCA4 deficiency
Presenter: Alina Grecea
Session: Poster session 19